Alkyl Amines conducted their conference call today at 4 pm.
Here are the key takeaways π
Business Updates:
β’ Much of growth contributors was value growth.
β’ Around 1/3 growth delivered by volume and 2/3 in volume. There were certain supply chin issue, leading to lower growth ion volume.
Growth:
β’ Co. is fairly optimistic on volume, with respect to sales in Pharma, as Pharma is going well.
β’ 3-5 year Volume growth target: 15%+ CAGR.
β’ There can be mid blip due to expansion.
Acetonitrile:
β’ Alkyl does not have much higher share, while most of the acetonitrile is imported, which co. is targeting. Hence co. added expansion here.
β’ Co. focusing on increasing the domestic share, while there is big export market, but not targeting as of now.
Methyl Amines:
β’ Increase in capacity of ~150 Tonnes per day, which was completed last year.
β’ Already expanded DMA, HCL derivatives, and most of it is internally consumed.
Ethyl Amines Investment:
β’ CAPEX would be 300 cr. This will increase capacity by 30%.
β’ Certain part is internally consumed.
Revenue Mix:
β’ Agrochemical and Pharma has 70% contribution of which Pharma shares ~45% of total revenue.
β’ While rest is from Dyestuff, Water Treatment, Rubber Chemical and miscellaneous sector.
Capacity Utilization:
β’ Most plants are running at fairly high utilization, and there some head room. But not much higher, hence expansion added.
Margin:
β’ This year quarter margin was decline due to increase in raw material price.
Industry Growth:
β’ Lost of SME and MSME has started using domestic product.
β’ Supply Chain is not that difficult nowadays.
β’ While business is seeing good growth in India.
Covid:
β’ 2nd wave impacted many employees of Alkyl, with respect to last year. However now there is recovery and 80-90% are recovered and there is not much impact on plant.
CAPEX:
β’ De-bottlenecking existing capacity, and is Scouting for land.
β’ Acetonitrile will have expansion 120cr.
β’ This year spend was ~150 cr and next year expense is targeted to be ~200cr.
β’ There is headroom of land in Kumkum and Dahej and new land to be acquire next year.
Plans:
β’ Previously, Alkyl has grown 10-15% in terms of volume and co. is not seeing any slowdown in this volume growth (with some exception)
β’ India is growing well, which will have domestic growth in amines segment.
Customers:
β’ Almost 99% of the customer are repeat customer.
β’ All the top 10 customers of co. are 10 years old customers and certain are 30-40 years old.
Management Bandwidth:
β’ There are younger people in the team who are already in the team from past few years, which can lead the company in future.
For more discussion on Equity research and OI analysis
#Cadila Healthcare conducted their conference call yesterday for Q4 FY2021
"Cadila is 2nd larget growing company in Pharma space"
Here are the key takeaways π
Business Updates:
β’ India business grew 20% (includes human health, consumer wellness, & animal wellness)- 16.4BilRs.
β’ US (generic and Sepciality)- 16.03Bill Rs. QoQ decline
β’ Emerging Market growth- 11%: 2.93BilRs Sales.
β’ Launched 7 new product and approvals of 9 product.
Revenue Mix:
β’ Human Health (India)- 21% growth (YoY).- 11.04BilRs
β’ Branded Generic Business grew 24% YoY
β’ Gained market share in Pain Mgmt, Anti-Effective, Anti-Diabetic.
β’ Market Share in Gyno, Pain Mgmt, Respiratory was maintained.
β’ Animal Health- 17% growth.
#SHKhelkar conducted their conference call today at 2:00 PM
"Expected to continue the momentum (~15% growth) and improve the margins"
Here are the key takeaways π
Business Updates:
β’ All the segment grew well. Acquired new customer in the domestic market.
β’ Net debt reduce by 132cr owing to increase in CF.
β’ Did the acquisition of Nova in this quarter.
β’ Co. focus on improving the Cash Flow generation and strengthening Balance Sheet.
Domestic Market (Covid)
β’ All the domestic segment grew well, and there was no impact on customer side in domestic market.
β’ Covid did had little impact over the segment, however growth momentum again picked up.
β’ Expected to growth 12-13% over coming year.
IG Petrochemicals Ltd. Conducted their conference call today at 3:30 pm.
" To become a well diversified chemical company with leadership in PAN* Industry. "
Here are the key takeaways π...
Business Overview
- Company has given robust growth in both QoQ and YoY basis.
- They still maintain their position of being the largest manufacturer of phthalic Anhydride (PAN) and maleic anhydride.(MAN)
- With government demand being bullish on downstream products like Paints, Plasticizers, UPR and all , there will be demand of PAN in domestic markets.
- They have a positive correlation with the infrastructure industry leading to a strong demand growth.
Balaji Amines conducted their Conference Call today at 4:00 pm.
Here are the key takeaways π
Business Updates:
β’ EBIDTA growth- 78% Driver were increasing demand and improving price realization.
β’ Zero debt co. on standalone basis.
β’ Certain product are now exported to China.
Ethylamines:
β’ With implementation of new technology the cost of production is expected to lower.
β’ Demand is India is expected to increase by 12-15% over years.
β’ Import of Ethylamines is 9,000 Tones in India.
β’ Majority will be sell directly in market.